← Back to Clinical Trials
Recruiting EARLY_Phase 1 NCT06538298

NCT06538298 Title: A Multimodal Exercise Program With Gamification for Parkinson Disease (MEP+G)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06538298
Status Recruiting
Phase EARLY_Phase 1
Sponsor California State University, Northridge
Condition Parkinson Disease
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2024-09-15
Primary Completion 2026-05-26

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Multimodal Exercise Program with Gamification

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.

This trial targets 50 participants in total. It began in 2024-09-15 with a primary completion date of 2026-05-26.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In this pilot study the research will explore whether exercises and the outcome measures would be acceptable to conduct a more detailed research study. This 8 week pilot study will utilize a comprehensive exercise program that includes non-contact boxing along with computerized games for individuals with Parkinson Disease.

Eligibility Criteria

Inclusion Criteria: * Hoehn and Yahr stages 1-3 disease as determined by primary care physician, neurologist, or movement disorder specialist * diagnosis of idiopathic Parkinson's Disease * ability to ambulate with or without an assistive device * transportation to and from testing site * ability to stand unassisted for 10 minutes * stable on Parkinson's disease medications for 3 months as determined by physician * medical clearance by their PCP, neurologist, or movement disorder specialist to participate in a moderate to vigorous exercise program. Exclusion Criteria: * other neurological disease other than Parkinson's disease * having had deep brain stimulation within the past 3 months , as determined by their physician * currently participating in a Rock Steady boxing program * self-report participation in moderate to vigorous exercise greater than 60 minutes per week. * required

Contact & Investigator

Central Contact

Andrew S Bartlett, PhD

✉ Andrew.Bartlett@csun.edu

📞 5857646717

Principal Investigator

Andrew S Bartlett, PhD

PRINCIPAL INVESTIGATOR

California State University, Northridge

Frequently Asked Questions

Who can join the NCT06538298 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, up to 80 Years, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT06538298 trial and what does that mean for participants?

Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.

Is NCT06538298 currently recruiting?

Yes, NCT06538298 is actively recruiting participants. Contact the research team at Andrew.Bartlett@csun.edu for enrollment information.

Where is the NCT06538298 trial being conducted?

This trial is being conducted at Ventura, United States.

Who is sponsoring the NCT06538298 clinical trial?

NCT06538298 is sponsored by California State University, Northridge. The principal investigator is Andrew S Bartlett, PhD at California State University, Northridge. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology